Exploring the Role of Formulations in Enhancing Drug Development
Drug development has undergone several changes over the years, organisations have capacities to screen an abundance of targets and compounds and discard those with low probability of success. Formulation plays a pivotal role at every step of the intricate journey of drug development. From the initial stages of testing potential compounds to the final phases of toxicological studies, the formulation of drugs is a critical determinant of efficacy and toxicity studies. Failure to consider formulation aspects early on can lead to the premature dismissal of promising compounds.
Choosing Animal Models and Route Selection
Selecting the appropriate animal model and route of administration is a critical decision that can significantly impact the outcome of preclinical studies. Each route offers distinct advantages and challenges, requiring careful consideration based on study objectives and the pharmacological target under investigation.
For instance, the subcutaneous route is often preferred for establishing pharmacokinetic-pharmacodynamic (PK-PD) relationships due to its rapid absorption and accessibility. On the other hand, the intraperitoneal route, while bypassing intestinal barriers, presents formulation challenges that must be addressed.
Among the various administration routes, oral administration is the most common but comes with its own set of challenges. Systemic absorption can be influenced by factors such as solubility, dissolution rate, and gastrointestinal physiological differences between species.
What is CYP3A4?
Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme primarily located in the liver but also found in the intestines. It is involved in the metabolism of a wide range of endogenous substances, such as steroids and fatty acids, and xenobiotics, such as drugs and toxins, that enter the body. CYP3A4 plays a key role in the oxidation of these substances, which is a crucial step in their metabolism and elimination from the body. This enzyme is responsible for breaking down many drugs, making it a critical factor in determining drug clearance and pharmacokinetics.
Take, for example, the enzyme CYP3A4, which plays a crucial role in drug metabolism. Variations in its activity levels across different animal models must be considered when selecting an appropriate model for pharmacokinetic studies. Dogs, for instance, exhibit altered expression and activity of CYP3A4, leading to potential discrepancies in predicting human pharmacokinetics. Moreover, differences in gastric pH between dogs and humans necessitate pre-treatment methods to ensure consistency, especially for pH sensitive compounds.
Monkeys, although more expensive models, offer a closer representation of human metabolism, making them preferred models when CYP3A4 activity is a factor. Conversely, rats lack a gall bladder and exhibit continuous bile excretion, impacting the absorption of lipophilic compounds undergoing micellar solubilization. Additionally, the expression and activity of CYP3A4 in rats differ from that in humans.
Understanding the Impact of Excipients
Excipients, the inactive ingredients in formulations, can significantly influence the proportion of drug that can be absorbed from the GI tract into the blood stream. While they do not directly contribute to the therapeutic action of the drug, they exert profound effects on its pharmacological behaviour and overall efficacy. Understanding the impact of excipients is essential for optimizing drug formulations, as the combination of these inactive ingredients can significantly influence the drug’s pharmacodynamic response and overall effectiveness in clinical settings. Excipients interact with biological functions in various ways, influencing the pharmacokinetics and pharmacodynamics of the active drug substance. For instance, they can affect drug solubility, stability, and bioavailability, thereby modulating the drug’s absorption, distribution, metabolism, and excretion (ADME) profile. Excipients may enhance drug dissolution rates, leading to faster onset of action, or they can hinder drug absorption by forming complexes or altering membrane permeability. One of the critical roles of excipients is their influence on dose-response relationships. The presence of certain excipients in a formulation can alter the pharmacological response of the drug, leading to changes in its potency, efficacy, or safety profile. Therefore, careful selection and optimization of excipients are essential to ensure predictable and reproducible dose-response relationships. Our team of experts at SeraNovo possess in-depth knowledge of excipients and leverage this understanding to design formulations that meet specific therapeutic objectives. We specialize in tailoring formulations to specific dose requirements, particularly for high drug-load liquids, ensuring optimal outcomes.
Navigating Toxicology Studies
Toxicology studies represent a pivotal phase in the drug development process, where the safety profile of a potential therapeutic agent is rigorously assessed. Unlike efficacy evaluations, toxicology studies typically involve administering drug doses that far exceed those intended for therapeutic use. Consequently, the formulation strategies employed in toxicology testing differ significantly from those aimed at assessing efficacy. As a result, formulations must be tailored to deliver high-drug concentrations while minimizing formulation-related toxicity or confounding factors that could obscure toxicological findings. Several challenges specific to toxicology formulations warrant careful consideration. High drug-load formulations may exhibit physical instability, such as aggregation or precipitation, which can hinder accurate dosing and result in variable drug exposure. At SeraNovo, we prioritize these considerations and fully understand our clients’ intended use of formulations, aiming to enhance the safety and efficacy profiles of compounds.
Why SeraNovo?
Formulations serve as the backbone of successful drug development, influencing every stage of the journey from animal model selection to toxicology studies. At SeraNovo, we distinguish ourselves with our proprietary HyGlass™ and LiGlass™ platforms, which have consistently proven to be the best for advancing challenging molecules through preclinical testing and into the clinic. Our expertise lies in developing high drug-load formulations that minimize the excipients and maximize absorption, enabling high dose administration.
We reduce manufacturing complexity and costs, making high-quality drugs more affordable. By working closely with our clients, we tailor solutions that meet their specific needs, accelerating the drug development process to bring life-saving medications to patients faster.
